Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-04-26
2011-04-26
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C436S064000, C436S063000, C536S023100
Reexamination Certificate
active
07932036
ABSTRACT:
We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.
REFERENCES:
patent: 4773455 (1988-09-01), Lessard
patent: 5238922 (1993-08-01), Graham et al.
patent: 5242974 (1993-09-01), Holmes
patent: 5384261 (1995-01-01), Winkler et al.
patent: 5405783 (1995-04-01), Pirrung et al.
patent: 5412087 (1995-05-01), McGall et al.
patent: 5420245 (1995-05-01), Brown et al.
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5429807 (1995-07-01), Matson et al.
patent: 5436327 (1995-07-01), Southern et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5472672 (1995-12-01), Brennan
patent: 5491164 (1996-02-01), De Solms et al.
patent: 5504212 (1996-04-01), De Solms et al.
patent: 5523430 (1996-06-01), Patel et al.
patent: 5527681 (1996-06-01), Holmes
patent: 5529756 (1996-06-01), Brennan
patent: 5532128 (1996-07-01), Eggers
patent: 5532359 (1996-07-01), Marsters et al.
patent: 5534537 (1996-07-01), Ciccarone et al.
patent: 5545531 (1996-08-01), Rava et al.
patent: 5554501 (1996-09-01), Coassin et al.
patent: 5556752 (1996-09-01), Lockhart et al.
patent: 5561072 (1996-10-01), Saito
patent: 5571639 (1996-11-01), Hubbell et al.
patent: 5578629 (1996-11-01), Ciccarone et al.
patent: 5585359 (1996-12-01), Breslin et al.
patent: 5593838 (1997-01-01), Zanzucchi et al.
patent: 5599695 (1997-02-01), Pease et al.
patent: 5602098 (1997-02-01), Sebti et al.
patent: 5624711 (1997-04-01), Sundberg et al.
patent: 5658734 (1997-08-01), Brock et al.
patent: 5661161 (1997-08-01), Anthony et al.
patent: 5700806 (1997-12-01), Doll et al.
patent: 5721236 (1998-02-01), Bishop et al.
patent: 5750567 (1998-05-01), Baudoin et al.
patent: 5756528 (1998-05-01), Anthony
patent: 5767274 (1998-06-01), Kim
patent: 5780492 (1998-07-01), Dinsmore et al.
patent: 5807852 (1998-09-01), Doll et al.
patent: 5843941 (1998-12-01), Marsters et al.
patent: 5852010 (1998-12-01), Graham et al.
patent: 5856326 (1999-01-01), Anthony et al.
patent: 5856439 (1999-01-01), Clerc
patent: 5859015 (1999-01-01), Graham et al.
patent: 5861529 (1999-01-01), Baudoin et al.
patent: 5869682 (1999-02-01), DeSolms
patent: 5872135 (1999-02-01), DeSolms
patent: 5880140 (1999-03-01), Anthony
patent: 5889053 (1999-03-01), Baudoin et al.
patent: 5891889 (1999-04-01), Anthony et al.
patent: 5936097 (1999-08-01), Commerçon et al.
patent: 5939557 (1999-08-01), Anthony et al.
patent: 5958939 (1999-09-01), Afonso et al.
patent: 5965539 (1999-10-01), Sebti et al.
patent: 5965578 (1999-10-01), Graham et al.
patent: 5968952 (1999-10-01), Venet et al.
patent: 5968965 (1999-10-01), Dinsmore et al.
patent: 5972966 (1999-10-01), DeSolms
patent: 5972984 (1999-10-01), Anthony et al.
patent: 5976851 (1999-11-01), Brown et al.
patent: 6004755 (1999-12-01), Wang
patent: 6037350 (2000-03-01), Venet et al.
patent: 6133305 (2000-10-01), Tang et al.
patent: 6169096 (2001-01-01), Venet et al.
patent: 6177432 (2001-01-01), Angibaud et al.
patent: 6187786 (2001-02-01), Venet et al.
patent: 6218114 (2001-04-01), Peck et al.
patent: 6218122 (2001-04-01), Friend et al.
patent: 6271002 (2001-08-01), Linsley et al.
patent: 6271210 (2001-08-01), Sivaraman et al.
patent: 6284764 (2001-09-01), Kath et al.
patent: 6306897 (2001-10-01), Uckun et al.
patent: 2005/0003422 (2005-01-01), Raponi
patent: 2007/0048782 (2007-03-01), Raponi
del Poeta et al. Blood 2003, 101:2125-2131.
Hill, et al. “Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited.” Critical Reviews in Oncology/Hematology, Jan. 2003, vol. 33 No. 1 pp. 7-23.
Mosesso, et al. “The novel human gene aprataxin is directly involved in DNA single-strand-break repair.” Cellular and Molecular Life Sciences, Feb. 2005, vol. 62, No. 4, pp. 485-491.
Zimmerman , et al., “Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies” American Society of Clinical Oncology, Dec. 2004, vol. 22, No. 23, pp. 4816-4822.
Nowicki, et al., “Chronic myelogenous leukemia molecular signature” Oncogene, Jun. 2003, vol. 22, No. 25, pp. 3952-3963.
PCT International Search Report, PCT application No. PCT/US08/56636, Alexandria, Virginia, dated Jul. 7, 2008, 5 pgs.
Ahel et al. (2006) The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates, Nature 443:713-716.
Bivona et al. (2003) Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1, Nature 424:694-698.
Bos (1989)RasOncogenes in Human Cancer: A review, Cancer Res 49:4682-4689.
Bullinger et al. (2004) Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia, N Engl J Med 350:1605-1616.
Burger et al. (2005) Activating Mutations in c-KIT and PDGFRalpha Are Exclusively Found in Gastrointestinal Stromal Tumors and Not in Other Tumors Overexpressing these Imatinib Mesylate Target Genes, Cancer Biol Ther 4:1270-1274.
Chang et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer, Lancet 362:362-369.
Chen et al. (2005) FLT3/ITD Mutation Signaling Includes Suppression of SHP-1, J Biol Chem 280:5361-5369.
Cox et al (2002) Farnesyltransferase inhibitors: promises and realities, Curr Opin Pharmacol 2:388-393.
Ebinu et al. (1998) RasGRP, a Ras Guanyl Nucleotide- Releasing Protein with Calcium- and Diacylglycerol-Binding Motifs, Science 280:1082-1086.
Ehmann et al. (2006) Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations Leuk Lymphoma 47:1387-1391.
End et al. (2001) Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro, Cancer Res 61:131-137.
Feldkamp et al. (2001) Isotype-specific RasGTP-Levels Predict the Efficacy of Farnesyl Transferase Inhibitors against Human Astrocytomas regardless ofRasMutational Status, Cancer Res 61:4425-4431.
Geman et al. (2004) Classifying Gene Expression Profiles from Pairwise mRNA Comparisons, Stat Appl Genet Mol Biol 3:30.
Holleman et al. (2004) Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment, N Engl J Med 351:533-542.
Illmer et al. (2005) Activation of theRASPathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts, Clin Cancer Res 11:3217-322.
Jansen et al. (2005) Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling, J Clin Oncol 23:732-740.
Karp et al. (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial, Blood 97:3361-3369.
Kawasaki et al. (1998) A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia, Proc Natl Ac
Fan Hongtao
Raponi Mitch
Wang Yixin
Bausch Sarae
Veridex, LLC
Volyn Todd
LandOfFree
Methods of determining acute myeloid leukemia response to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of determining acute myeloid leukemia response to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of determining acute myeloid leukemia response to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681197